Abstract
Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Current Genomics
Title: Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Volume: 3 Issue: 4
Author(s): S. Ortega, M. Malumbres and M. Barbacid
Affiliation:
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Abstract: Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Export Options
About this article
Cite this article as:
Ortega S., Malumbres M. and Barbacid M., Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350444
DOI https://dx.doi.org/10.2174/1389202023350444 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives
Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins
Current Protein & Peptide Science Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Synthesis of New Benzimidazole and Benzothiazole Disulfide Metal Complexes as G-quadruplex Binding Ligands
Anti-Cancer Agents in Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology